2020 Annual Meeting - Controversies in the Management of Adult Sarcomas

Soft tissue sarcomas are rare and involve a well-integrated multi-modality approach to optimize outcomes and decrease morbidity. A recent report published by Sarcoma UK showed that 75% of the population "do not know what sarcoma is." This lack of knowledge has translated to the incidence of unplanned excisions, increasing morbidity, and inferior outcomes. It is also one of the many reasons that sarcomas should be managed at a high-volume center. Management of sarcomas in such centers lead to improved oncologic outcomes, and thus, it is important for oncologists to have a good working knowledge and multi-disciplinary collaboration. In the proposed didactic session on "Controversies in the Management of Adult Sarcomas", speakers will provide an overview of adult sarcoma and extensively discuss management for common and often controversial clinical scenarios that many sarcoma providers encounter such as, unplanned excisions, pediatric sarcomas in adults, hypofractionated radiotherapy, and use of chemotherapy in localized disease.

The course will provide updates in data on these topics. In addition, speakers will engage the attendees during the session by incorporating an audience response system (ARS) and specific inquiry after each controversial topic is presented (Campfire Method). We plan to begin with ARS questions, view the results, and ask the same ARS questions at the end of the session to gauge if views of the audience have changed based on the information presented. We also plan to query “the MedNet” and poll subjects using social media platforms on these controversial topics. 

Target Audience

The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation physicists, radiation therapists, radiation dosimetrists, nurses, specialists, and radiation oncology residents. 

Learning Objectives

    1. Discuss the management of unplanned excisions and integration of care across disciplines.
    2. Analyze the data regarding radiation in RPS, pediatric sarcomas in adults and chemotherapy in localized soft tissue sarcomas and determine optimal use on varying patient populations.
    3. Implement the knowledge learned to educate patients on expectations, outcomes and methods to minimize toxicity.
    Course summary
    Available credit: 
    • 1.25 Certificate of Attendance
      This activity was designated for 1.25 AMA PRA Category 1 Credit™.
    • 1.25 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.

    Course opens: 
    10/28/2020
    Course expires: 
    11/30/2020
    Cost:
    $0.00
    Rating: 
    0
    • Jonathan Trent, MD, PhD is employed at University of Miami, Sylvester Comprehensive Cancer Center and has no financial relationships with a commercial interest. 
    • David M. King, MD is employed at Medical College of Wisconsin and has no financial relationships with a commercial interest. 
    • Manpreet Bedi, MD is employed at Medical College of Wisconsin and has no financial relationships with a commercial interest. 
    • Yen-Lin Evelyn Chen is employed at Massachusetts General Hospital and has family employed at Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Dr. Chen has no financial relationships with a commercial interest. 

    The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

    ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

    Available Credit

    • 1.25 Certificate of Attendance
      This activity was designated for 1.25 AMA PRA Category 1 Credit™.
    • 1.25 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.

    Price

    Cost:
    $0.00
    Please login or register to take this course.

    Policies: 
        • No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
        • No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
        • ASTRO staff cannot make modifications to your submitted materials.
     

    Required Hardware/software

    One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.